161 related articles for article (PubMed ID: 29090664)
1. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.
Megias-Vericat JE; Martinez-Cuadron D; Herrero MJ; Alino SF; Poveda JL; Sanz MA; Montesinos P
Curr Drug Metab; 2018; 19(1):55-74. PubMed ID: 29090664
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics and the treatment of acute myeloid leukemia.
Megías-Vericat JE; Montesinos P; Herrero MJ; Bosó V; Martínez-Cuadrón D; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics; 2016 Jul; 17(11):1245-1272. PubMed ID: 27381050
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia.
Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Poveda JL; Montesinos P
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456712
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
5. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Rojas L; Martínez-Cuadrón D; Hervás D; Boluda B; García-Robles A; Rodríguez-Veiga R; Martín-Cerezuela M; Cervera J; Sendra L; Sanz J; Miguel A; Lorenzo I; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 May; 58(5):1197-1206. PubMed ID: 27701910
[TBL] [Abstract][Full Text] [Related]
6. Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; Martínez-Cuadrón D; Herrero MJ; Rodríguez-Veiga R; Solana-Altabella A; Boluda B; Ballesta-López O; Cano I; Acuña-Cruz E; Cervera J; Poveda JL; Sanz M; Aliño SF; Montesinos P
Leuk Lymphoma; 2021 Mar; 62(3):659-668. PubMed ID: 33135528
[TBL] [Abstract][Full Text] [Related]
7. Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; Martínez-Cuadrón D; Herrero MJ; Rodríguez-Veiga R; Solana-Altabella A; Boluda B; Ballesta-López O; Cano I; Acuña-Cruz E; Cervera J; Poveda JL; Sanz MÁ; Aliño SF; Montesinos P
Pharmacogenet Genomics; 2021 Aug; 31(6):133-139. PubMed ID: 33675324
[TBL] [Abstract][Full Text] [Related]
8. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies.
Megías-Vericat JE; Rojas L; Herrero MJ; Bosó V; Montesinos P; Moscardó F; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics J; 2015 Apr; 15(2):109-18. PubMed ID: 25558979
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol.
Puty TC; Sarraf JS; Do Carmo Almeida TC; Filho VCB; de Carvalho LEW; Fonseca FLA; Adami F
Syst Rev; 2019 May; 8(1):109. PubMed ID: 31053175
[TBL] [Abstract][Full Text] [Related]
10. Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines.
Kim DS; Kang KW; Lee SR; Park Y; Sung HJ; Kim SJ; Choi CW; Kim BS
Ann Hematol; 2015 Sep; 94(9):1485-92. PubMed ID: 25944346
[TBL] [Abstract][Full Text] [Related]
11. The Role of Anthracyclines in Acute Myeloid Leukemia Consolidation.
Byun JM; Lee JO; Suh KJ; Lee J; Shin DY; Koh Y; Hong J; Bang SM; Kim I; Yoon SS
Anticancer Res; 2020 Jan; 40(1):357-366. PubMed ID: 31892587
[TBL] [Abstract][Full Text] [Related]
12. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
DeAngelo DJ; Stein EM; Ravandi F
Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
14. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Ann Hematol; 2018 Jul; 97(7):1115-1153. PubMed ID: 29680875
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.
Megías-Vericat JE; Herrero MJ; Rojas L; Montesinos P; Bosó V; Moscardó F; Martínez-Cuadrón D; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics J; 2016 Feb; 16(1):30-40. PubMed ID: 26644203
[TBL] [Abstract][Full Text] [Related]
16. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
[TBL] [Abstract][Full Text] [Related]
17. Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.
He H; Yin J; Li X; Zhang Y; Xu X; Zhai M; Chen J; Qian C; Zhou H; Liu Z
Eur J Clin Pharmacol; 2015 Mar; 71(3):293-302. PubMed ID: 25567217
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape.
Al-Antary ET; Gupte A; Ravindranath Y
Indian J Pediatr; 2024 Feb; 91(2):176-183. PubMed ID: 37450248
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
20. Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Guolo F; Minetto P; Clavio M; Miglino M; Lemoli RM; Gobbi M
Biosci Trends; 2017 Mar; 11(1):110-114. PubMed ID: 28123146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
